Echarte MJC, Hechavarría PS, Alfonso RE

Idioma: Español
Referencias bibliográficas: 41
Paginas: 460-472
Archivo PDF: 505.63 Kb.

RESUMEN

En la práctica cardiológica en Cuba son frecuentemente referidos pacientes con sospecha clínica de hipertensión pulmonar, el mayor porcentaje de los casos para confirmación diagnóstica, definición de causas y abordaje terapéutico. El criterio para definirla es una presión media en la arteria pulmonar mayor de 25 mmHg. La enfermedad puede presentarse en distintos procesos clínicos, que se clasifican en 5 grupos. En este artículo se muestra una revisión de la bibliografía y las publica-ciones más recientes acerca de este tema.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hyperten-sion: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the Eu-ropean Society of Cardiology (ESC) and the Eu-ropean Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congeni-tal Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. [DOI]

2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynam-ic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J [Internet]. 2019 [citado 10 Ene 2021];53(1):1801913. Disponi-ble en: https://doi. org/10. 1183/13993003. 01913-2018

3. Barberà JA, Román A, Gómez-Sánchez MA, Blan-co I, Otero R, López-Reyes R, et al. Diagnóstico y tratamiento de la hipertensión pulmonar (Norma-tiva SEPAR) [Internet]. Barcelona: Editorial Res-pira [citado 10 Ene 2021]; 2017. Disponible en: https://www. sogapar. info/wp-content/uploads/2016/12/7-Normativa-SEPAR-hipertension-pulmonar. pdf

4. Portillo K, Santos S, Madrigal I, Blanco I, Pare C, Borderias L, et al. Study of the BMPR2 gene in pa-tients with pulmonary arterial hypertension. Arch Bronconeumol. 2010;46(3):129-34. [DOI]

5. Pousada G, Baloira A, Vilariño C, Cifrian JM, Valverde D. Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. PLoS One [Internet]. 2014 [citado 12 Ene 2021]; 9(6):e100261. Disponible en:https://doi. org/10. 1371/journal. pone. 0100261

6. Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, et al. Pulmonary veno-occlusive di-sease. Eur Respir J. 2016;47(5):1518-34. [DOI]

7. Tenorio J, Navas P, Barrios E, Fernández L, Neva-do J, Quezada CA, et al. A founder EIF2AK4 muta-tion causes an aggressive form of pulmonary ar-terial hypertension in Iberian Gypsies. Clin Genet. 2015;88(6):579-83. [DOI]

8. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589-96. [DOI]

9. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, et al. World Health Organiza-tion Pulmonary Hypertension group 2: pulmo-nary hypertension due to left heart disease in the adult - A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913-33. [DOI]

10. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S, et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest. 2014;145(5):1064-70. [DOI]

11. Gómez-López EA. Hipertensión pulmonar asocia-da a enfermedad cardiaca izquierda. Enfoque diagnóstico y terapéutico. Rev Colomb Cardiol. 2017;24(Suppl 1):55-64. [DOI]

12. Barnett CF, Selby VM. Overview of WHO Group 2 pulmonary hypertension due to left heart dis-ease. Advances in Pulmonary Hypertension. 2015; 14(2):70-8. [DOI]

13. Seeger W, Adir Y, Barberà JA, Champion H, Cogh-lan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62(25 Suppl):D109-16. [DOI]

14. Phan K, Jo HE, Xu J, Lau EM. Medical Therapy Versus Balloon Angioplasty for CTEPH: A Sys-tematic Review and Meta-Analysis. Heart Lung Circ. 2018;27(1):89-98. [DOI]

15. Barberà JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, et al. Estándares asistencia-les en hipertensión pulmonar: Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la So-ciedad Española de Cardiología (SEC). Arch Bron- coneumol. 2008;44(2):87-99. [DOI]

16. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. [DOI]

17. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. [DOI]

18. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pul-monary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. [DOI]

19. Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Ma-cari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7. [DOI]

20. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evi-dence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):35S-62S. [DOI]

21. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epo-prostenol infusion in primary pulmonary hyper-tension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8. [DOI]

22. Barberà JA, Blanco I. Management of Pulmonary Hypertension in Patients with Chronic Lung Dis-ease. Curr Hypertens Rep. 2015;17(8):62. [DOI]

23. López Guide MJ, Pérez de la Sota E, Forteza Gil A, Centeno Rodríguez J, Eixeres A, Velázquez MT, et al. Pulmonary thromboendarterectomy in 106 pa-tients with chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2015;51(10): 502-8. [DOI]

24. Coronel ML, Chamorro N, Blanco I, Amado V, Del Pozo R, Pomar JL, et al. Medical and surgical management for chronic thromboembolic pul-monary hypertension: a single center experience. Arch Bronconeumol. 2014;50(12):521-7. [DOI]

25. Escribano-Subías P, Del Pozo R, Román-Broto A, Domingo Morera JA, Lara-Padrón A, Elías Her-nández T, et al. Management and outcomes in chronic thromboembolic pulmonary hyperten-sion: From expert centers to a nationwide per-spective. Int J Cardiol. 2016;203:938-44. [DOI]

26. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmo-nary hypertension. N Engl J Med. 2013;369(4):319-29. [DOI]

27. Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet RespirMed. 2017;5(10):785-94. [DOI]

28. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iN-opErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, place-bo-controlled trial. J Am Coll Cardiol. 2008;52(25): 2127-34. [DOI]

29. Olsson KM, Wiedenroth CB, Kamp JC, Breitheck-er A, Fuge J, Krombach GA, et al. Balloon pulmo-nary angioplasty for inoperable patients with chronic thromboembolic pulmonary hyperten-sion: the initial German experience. Eur Respir J [Internet]. 2017 [citado 15 Ene 2021];49(6):1602409. Disponible en:https://doi. org/10. 1183/13993003. 02409-2016

30. Velázquez Martín M, Albarrán González-Trevilla A, Alonso Charterina S, García Tejada J, Cortina Romero JM, Escribano Subías P. Angioplastia pul-monar con balón en la hipertensión pulmonar tromboembólica crónica no operable. Experien-cia inicial en España en una serie de 7 pacientes. Rev Esp Cardiol. 2015;68(6):535-7. [DOI]

31. Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011;38(6): 1343-8. [DOI]

32. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-44. [DOI]

33. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hy-pertension. N Engl J Med. 1996;334(5):296-301. [DOI]

34. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival in patients with class III idiopathic pulmonary arterial hyperten-sion treated with first line oral bosentan com-pared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12): 1025-30. [DOI]

35. Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, et al. Assessment of survival in pa-tients with primary pulmonary hypertension: im-portance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. [DOI]

36. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Ex-ercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104(4): 429-35. [DOI]

37. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Ky-otani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865-70. [DOI]

38. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-ter-minal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hyperten-sion. Chest. 2006;129(5):1313-21. [DOI]

39. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pul-monary hypertension. J Am Coll Cardiol. 2002; 39(7):1214-9. [DOI]

40. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annu-lar displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174(9):1034-41. [DOI]

41. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hy-pertension. Eur Respir J. 2005;25(2):244-9. [DOI]